Compare Incyte Corporation (INCY) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Global X SuperDividend ETF — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Global X SuperDividend ETF trades at $24.57. The key difference: Incyte Corporation is trading nearer its 52-week high, Global X SuperDividend ETF nearer its low. Which is the better fit depends on your goals.
| INCY | SDIV | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $129.93 | $26.34 |
52-Week Low | $81.61 | $22.90 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
SDIV, a US-listed ETF, trades at $24.585, down 0.26% on the day, with a bearish technical signal driven by moving averages. The fund offers a high dividend yield, with recent payouts of $0.18 per share. Technical indicators show neutral oscillators but overall selling pressure, with key support at $24 and resistance at $25.
The outlook for SDIV hinges on income-seeking demand amid market volatility, as highlighted by financial media. Risks include sensitivity to interest rates and geopolitical factors. Analyst sentiment is mixed, with some upgrades citing yield attractiveness, but the bearish technical trend warrants caution for near-term price appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
